Back to results
US 9,637,524 B2Granted
Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
AssigneeThe Regents of the University of California
InventorsR. Holland Cheng, Li Xing
Life of this patent
Estimating the term…
Abstract
This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems.
Claims14
A composition comprising:
- an hepatitis E virus (HEV) capsid protein comprising residues 112-608 of HEV ORF 2 protein of SEQ ID NO:
- 1(genotype 2), 4(genotype 1), 5(genotype 3), or 6(genotype 4), a first heterologous peptide, and a second heterologous peptide, wherein the first heterologous peptide is inserted at a position of the HEV ORF 2 protein that is immediately after residue Tyr485, and the second heterologous peptide is inserted after residue 608 of the HEV ORF2 protein;
- and
- a heterologous nucleic acid encapsulated in a chimeric virus-like particle (VLP) formed by the HEV capsid protein.
1 more element
An HEV capsid protein, comprising residues 112-608 of HEV ORF 2 protein of SEQ ID NO:
- 1(genotype 2), 4(genotype 1), 5(genotype 3), or 6(genotype 4), a first heterologous peptide, and a second heterologous peptide, wherein the first heterologous peptide is inserted into the portion of HEV ORF 2 immediately after residue Tyr485, and the second heterologous peptide is inserted after residue 608 of the HEV ORF2 protein, wherein the HEV capsid protein forms an HEV VLP.
Dependencies are inferred from the claim text.